Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Gallbladder Neoplasms 2Stomach Neoplasms 1Polyps 1Neuroendocrine Tumors 1Neoplasms 1Gallstones 1Digestive System Neoplasms 1Adenoma 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 4lanreotide 4Sunitinib 4Temozolomide 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Capecitabine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Quality of Life 2FAPI-46 2veliparib 1tivozanib 1tislelizumab 1telotristat ethyl 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1gallium Ga 68 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Cholecystectomy × Gastrointestinal × Clear all
NCT04780737 2021-03-03

Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Completed
230 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡